Mäkelä Lauri, Pétas Anssi, Mikkola Arto, Visapää Harri
Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Urology , University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Front Oncol. 2025 Jan 16;14:1326355. doi: 10.3389/fonc.2024.1326355. eCollection 2024.
This retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.
235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated. Additionally, the incidence of late urinary complications was recorded.
Median follow-up time was 11,6 years. 181 patients (77%) were classified as low-risk patients, while 52 patients (22,1%) were intermediate risk. The overall bRFS was 83,8% at 5 years and 72,4% at 10 years. 5- and 10-year OS were 97,8% and 87,8% respectively. There was no statistically significant difference in bRFS or OS between different risk groups. The rate of late urinary complications was 8,9%. Volume of prostate had a statistically significant effect on bRFS, as smaller prostate volumes led to worse bRFS.
This retrospective study shows that LDR brachytherapy is an effective treatment for low- and intermediate risk prostate cancer patients with relatively low but still significant risk of late urinary complications.
本回顾性研究旨在评估低剂量率近距离放射治疗局限性前列腺癌的长期疗效和泌尿系统毒性。
本研究纳入了235例接受低剂量率近距离放射治疗并随后在本中心进行随访的原发性前列腺癌患者。评估生化无复发生存期（bRFS）、总生存期（OS）和癌症特异性生存期（CSS）。此外，记录晚期泌尿系统并发症的发生率。
中位随访时间为11.6年。181例患者（77%）被归类为低风险患者，而52例患者（22.1%）为中风险患者。5年时总体bRFS为83.8%，10年时为72.4%。5年和10年的OS分别为97.8%和87.8%。不同风险组之间的bRFS或OS无统计学显著差异。晚期泌尿系统并发症发生率为8.9%。前列腺体积对bRFS有统计学显著影响，前列腺体积较小会导致bRFS较差。
本回顾性研究表明，低剂量率近距离放射治疗是治疗低风险和中风险前列腺癌患者的有效方法，尽管晚期泌尿系统并发症风险相对较低，但仍具有显著风险。
